On November 5, 2021 AimedBio reported that its novel brain tumor therapeutics, AMB302, was selected as a government-initiated drug development program by the Korean Drug Development Fund (KDDF).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AMB302 is a first-in-class ADC therapeutics targeting a brain tumor specific fusion oncogene.

AimedBio has confirmed significant tumor killing effect of AMB302 candidate.

AimedBio utilizes patients’ genetic/clinical data and patient-derived samples in the antibody development process, resulting in higher probability of clinical success.

(Press release, AimedBio, NOV 5, 2021, View Source;s_keyword=&s_where=&start=20 [SID1234656924])

bluebird bio has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On November 5, 2021 Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, reported it will host a comprehensive Investor Update event on Thursday, December 2nd, from 10:00am ET – 1:00pm ET (Press release, Delcath Systems, NOV 5, 2021, View Source [SID1234595225]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event will feature physicians discussing percutaneous hepatic perfusion, updated Focus trial data and the role of Hepzato Kit (melphalan hydrochloride for injection/Hepatic Delivery System) as a potential treatment for patients with hepatic-dominant metastatic ocular melanoma. Additionally, physicians will discuss the potential utility of Hepzato in treating colorectal cancer, intrahepatic cholangiocarcinoma, the unmet need in liver metastases and related clinical development strategies.

Event Details:

Event: Delcath Systems Virtual Investor Update Event
Date: Thursday, December 2, 2021
Time: 10:00am – 1:00 p.m. EST

To register for this event, please click here.

The live webcast of the event may be accessed through the Events and Presentation page of Delcath’s website, under the Investors section. The archived webcast and presentation will be available on the Company’s website after the event.

On November 5, 2021 Philogen reported that Stifel Conference provides an opportunity for investors to get a perspective of Philogen progresses and to meet CEO Dario Neri through a series of one-on-one meetings (Press release, Philogen, NOV 5, 2021, View Source [SID1234594677]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Co-founder, CEO and CSO, Prof. Dario Neri is giving a presentation on November 16, 2021.

On November 5, 2021 Race Oncology Limited ("Race") reported that congratulates Dr Joshua Brzozowski from the laboratory of Associate Professor Nikki Verrills, University of Newcastle, for winning the Best Poster Prize in the Biomarkers and Targeted Therapy section at the Hunter Cancer Research Symposium on November 4, 2021 (Press release, Race Oncology, NOV 5, 2021, View Source [SID1234594671]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation entitled "Preclinical efficacy of bisantrene for the treatment of breast cancer" describes the use of Zantrene (bisantrene dihydrochloride) in breast cancer cells and identified two key highlights:

Drug-resistant breast cancer cells are more sensitive to treatment with Zantrene compared to other anthracyclines, such as doxorubicin or epirubicin.
Zantrene has additive or synergistic activity when used with cyclophosphamide (a widely used breast cancer drug) in human breast cancer cell lines.
This presentation expands on results previously reported from the Verrills Laboratory (ASX announcement: 9 March 2021).